This vaccine is applied for active immunization against orthopoxviruses. This prophylactic agent is commonly used to help with easing the overall symptom load associated with mpox disease and smallpox disease. JYNNEOS is applied to establish active immunity and provides broad cross-protection against these two conditions. The main benefit is providing foundational protection, which is relevant for easing symptoms associated with acute or episodic changes, especially in situations where patients experience increased exposure risk.

The vaccine is applied in clinical settings that involve Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP), which are relevant in contexts involving heightened systemic burden. Furthermore, JYNNEOS is considered relevant as a prophylactic option for immunocompromised individuals and those with certain skin conditions like atopic dermatitis, supporting patients during difficult episodes by easing distress.

“The vaccine is applied when appropriate for conditions presenting with systemic or localized discomfort, assisting with maintaining a sense of stability during periods of heightened exposure risk.”

Quick Fact: Primary Therapeutic Role
Conditions	Mpox disease and Smallpox disease
Main Benefit	Mitigation of systemic imbalance and symptom burden
Key Use Scenario	Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP)

JYNNEOS is licensed for use in individuals determined to be at high risk for smallpox or mpox infection, but eligibility is strictly governed by regulatory status and individual patient history.

Contraindications and Core Eligibility

Category	Regulatory Status
Populations for Whom Use is Contraindicated	History of severe allergic reaction (e.g., anaphylaxis) to a previous dose of JYNNEOS or to a known component, such as gentamicin or ciprofloxacin.
Licensed Age Group	Adults 18 years of age and older (FDA and EMA).
Adolescents	12 to 17 years: Approved for use by the EMA. May be available under an Emergency Use Authorization (EUA) in the US.
Children	Below 12 years: Safety and efficacy have not been established under standard license.

Special Population Considerations

The vaccine's non-replicating design means that individuals with certain pre-existing conditions, which were contraindications for older smallpox vaccines, are generally eligible:

• Immunocompromised Persons: Use is permitted. However, regulatory warnings state that the immune response may be diminished in those with compromised immune systems.
• Atopic Dermatitis: The vaccine is not contraindicated for individuals with eczema or atopic dermatitis.
• Pregnancy and Lactation: Use may be considered if the potential benefits outweigh any potential risk, especially in high-risk individuals, as human data is limited but animal studies show no evidence of harm.

Interactions with other medicines and products

The primary concern regarding Jynneos (Smallpox and Mpox Vaccine, Live, Non-Replicating) interactions is the potential for other substances to interfere with the vaccine's ability to stimulate a protective immune response.

Pharmacodynamic Interactions

Immunosuppressive therapies, such as high-dose systemic corticosteroids, chemotherapy agents, and other medicines that suppress the immune system, may lead to a diminished immune response to Jynneos. This means the vaccine may be less effective in protecting individuals who are immunocompromised or receiving such treatments.

Absence of Pharmacokinetic Data

Official regulatory information notes that formal clinical studies assessing potential interactions between Jynneos and other medicinal products involving drug metabolism (e.g., CYP enzymes) or drug transporters have not been conducted. Therefore, no data exists on how Jynneos is affected by or affects the concentrations of these types of medicines.

Administration and Timing Constraints

Due to the lack of available interaction data, official labeling restricts the simultaneous use of Jynneos with certain other biological products:

• Other Vaccines: Concomitant administration with other vaccines should generally be avoided.
• Immunoglobulins: Administration with any immunoglobulin, including Vaccinia Immune Globulin (VIG), has not been studied and should be avoided due to the theoretical potential to interfere with the intended immune response.

No officially documented interactions exist for Jynneos with food, alcohol, or common herbal products.

How Jynneos Works

Jynneos acts by delivering antigens from the Modified Vaccinia Ankara (MVA) virus, a strain engineered to be non-replicating in human cells. This mechanism confines viral protein expression to the initial infection site without sustained systemic growth. The viral antigens are presented by antigen-presenting cells to the adaptive immune system, initiating two primary cascades.

First, the vaccine stimulates B-lymphocytes to differentiate into plasma cells, leading to the secretion of high levels of neutralizing antibodies. These antibodies bind to orthopoxvirus surface proteins, facilitating the rapid inactivation and clearance of potential invaders before cell entry. Second, the vaccine triggers the activation of specific CD4+ and CD8+ T-lymphocytes. This cell-mediated immune response provides a secondary mechanism, enabling CD8+ T-cells to identify and induce apoptosis in host cells presenting orthopoxvirus antigens, a process that modulates the concentration of infectious virions within tissues. The non-replicating nature of the MVA vector restricts the systemic spread of viral material, resulting in reduced localized inflammation and systemic activity compared to replicating viral vectors.

How to use Jynneos

The administration of Jynneos follows a standardized protocol involving a specific injection route and a two-dose series. The primary method of administration is a subcutaneous injection, typically delivered into the fatty tissue of the upper arm. The standard volume for this route, as well as for the alternative intramuscular route, is 0.5 mL per dose.

In specific dose-sparing scenarios, an intradermal injection into the forearm may be used. This method utilizes a reduced volume of 0.1 mL. For individuals without a history of prior vaccination against orthopoxviruses, a complete primary course consists of two doses administered at an interval of 4 weeks (28 days).

Preparation of the vaccine requires the vial—which contains an opaque, whitish-to-pale-yellow suspension—to be gently swirled for at least 30 seconds. Shaking the vial is prohibited. The suspension must be visually inspected for foreign particles or discoloration before use.

Certain populations, including immunocompromised individuals, require the full two-dose series regardless of previous vaccination history. If a second dose is delayed beyond the 28-day window, it should be administered as soon as possible without restarting the series. The vaccine must not be administered intravenously.

Research Evidence / Overview of Studies for Jynneos

1. The Evidence Framework for Smallpox Prevention

Research for the smallpox indication utilized a specific regulatory framework, as the disease is globally eradicated. Clinical trials measuring direct disease prevention in humans were not feasible for this indication. Therefore, research relied on established scientific principles known as the Animal Rule and the use of surrogate markers.

Researchers conducted randomized, comparative trials to study the immune response observed in healthy adults. The primary outcome measured in these human studies was the level of Vaccinia-neutralizing antibody titers. These antibodies are considered a regulatory proxy, or a surrogate marker, based on associations noted in decades of research involving older smallpox vaccines. Additionally, research examined survival and disease progression following orthopoxvirus exposure in non-human primate models.

2. Real-World Studies for Mpox Prevention

Research exploring the mpox indication primarily relies on real-world evidence derived from observational studies and surveillance data gathered during recent global outbreaks. These studies were applied in observational settings evaluating daily-life functioning among high-risk adults.

Researchers examined patterns related to confirmed mpox disease incidence between vaccinated and unvaccinated cohorts. Observational analyses reported differences in mpox case occurrence between groups who received the vaccine and those who did not. Findings also help contextualize how participants reported their experience regarding outcomes related to symptoms and illness severity. However, certainty remains low regarding the extent of clinical outcomes, as this research relied on observational study designs rather than randomized controlled trials (RCTs), introducing potential biases.

3. Immune Response and Research Gaps

Studies were conducted to specifically characterize the immune response in certain populations, including individuals with HIV infection or atopic dermatitis, where older smallpox vaccines were often not used. Research describes that these immune responses were sometimes observed at lower levels compared to the responses in healthy adult cohorts.

Follow-up durations for all studies were limited. Long-term outcomes are not fully established regarding the sustained correlation between the measured immune markers and clinical disease outcomes. A major limitation is the absence of large-scale, prospective RCTs against mpox, and data for certain groups, such as children, remain insufficient. Research is ongoing to better characterize the persistence of the observed immune response.

Key Studies & References Comparison of Vaccinia-Neutralizing Antibody Responses Following Vaccination with JYNNEOS or ACAM2000 in Healthy Smallpox Vaccine-Naïve Adults 18 Through 42 Years of Age (Study 7, referenced in package insert)

Common questions about Jynneos (FAQ)

---

Q: Is Jynneos the same as ACAM2000?

JYNNEOS is not the same as ACAM2000. JYNNEOS is classified by health authorities as a third-generation vaccine that uses a Modified Vaccinia Ankara (MVA) virus which is non-replicating, meaning it cannot multiply efficiently in human cells.

ACAM2000 is a second-generation vaccine that contains a live virus that does replicate in humans. These fundamental differences in the type of virus used lead to different safety profiles and administration protocols.

---

Q: How quickly does protection start after getting Jynneos?

The optimal immune response, as measured by studies, is generally seen 14 days after the second dose of the recommended two-dose series. Public health guidance suggests that administration within 4 days of a known or presumed exposure is associated with the highest potential to prevent disease onset. Receiving it between 4 and 14 days after exposure may still help reduce the severity of symptoms.

---

Q: Do I need a booster shot of Jynneos?

Currently, a booster or additional dose of JYNNEOS is not recommended by health authorities for individuals who have already completed the two-dose primary series. If you have previously recovered from mpox, additional doses are also not recommended at this time.

---

Q: Does Jynneos interact with common cold or flu medicines?

Official prescribing information notes that formal clinical studies assessing potential interactions between JYNNEOS and other medicines, including over-the-counter products like cold or flu medicines, have not been conducted. For this reason, official patient information emphasizes the importance of informing your healthcare provider about all prescription and non-prescription medicines, vitamins, and supplements.

---

Q: What research supports the use of Jynneos in people who have already been vaccinated for smallpox?

Clinical trials for JYNNEOS measured immune responses using antibody levels, which are considered a surrogate marker for protection. Studies specifically compared these antibody levels in both those who had never been vaccinated against smallpox and those who had received an older smallpox vaccine. The findings support the use of JYNNEOS regardless of a person’s childhood smallpox vaccination history, with public health guidance recommending the full two-dose series for all adults at risk.

---

Q: Has Jynneos been studied in different age groups, like older adults?

JYNNEOS is licensed for use in all adults 18 years of age and older. Real-world surveillance data, including information from adults over age 50, has provided observational evidence that suggests differences in rates of disease and hospitalization compared to unvaccinated individuals in this group.

---

Q: Is Jynneos effective against diseases other than monkeypox and smallpox?

Official regulatory documents indicate that JYNNEOS is licensed solely for the prevention of smallpox and mpox disease. It offers cross-protection against these two diseases as they are caused by related orthopoxviruses. It is not indicated for use against diseases caused by other virus families.

---

Q: Do I need to change my activities after getting the Jynneos shot?

Regulatory documents do not list specific restrictions on daily activities following JYNNEOS vaccination. However, patients may experience common temporary side effects like headache, fatigue, or muscle pain. These effects typically resolve within a few days.

---

Q: What is the typical cost of the Jynneos vaccine?

Funding for JYNNEOS is often provided through federal and state-supported public health programs for eligible high-risk individuals. Coverage may also be provided by private insurance plans, Medicare, and Medicaid, depending on current eligibility and policy.

---

Q: Is it possible to receive Jynneos if I have a history of heart problems?

A history of heart problems, such as prior myocarditis or pericarditis, is not a contraindication for JYNNEOS. Official guidance notes that individuals with underlying heart disease may need to discuss the potential benefits and theoretical risks of vaccination with their healthcare provider prior to administration.

---

Q: What does 'attenuated' mean in relation to the Jynneos virus?

Attenuated means the virus in the vaccine, the Modified Vaccinia Ankara (MVA) strain, has been significantly weakened. The virus is non-replicating, meaning it can only stimulate an immune response and cannot multiply extensively or cause widespread disease in human cells.

---

Q: What official guidance is available about Jynneos for travel?

Official travel guidance from authorities like the CDC describes the potential need for vaccination for travelers to certain countries if they anticipate activities that increase the risk of exposure. Completion of the two-dose series at least two weeks before travel is described as being necessary to achieve the optimal immune response.

---

Q: Does Jynneos help with shingles or chickenpox?

No. JYNNEOS is designed to prevent diseases caused by the Orthopoxvirus family (smallpox and mpox). Shingles and chickenpox are caused by the Herpesvirus family, which is unrelated. JYNNEOS does not offer protection against these diseases.

---

Q: Is there a maximum age limit for receiving Jynneos?

The JYNNEOS vaccine is fully licensed for use in adults 18 years of age and older. No specific upper age limit is listed as a contraindication in the official product information.

---

Q: If I was exposed to monkeypox, can Jynneos still help?

Yes, JYNNEOS can be used for Post-Exposure Prophylaxis (PEP). Official guidance states that vaccination within four days of exposure is associated with the highest potential for preventing disease onset. If the vaccine is administered between four and 14 days after exposure, it may still reduce the severity of symptoms.

---

Q: Why is Jynneos also called Imvamune or Imvanex?

The product is the same vaccine (MVA-BN), but it is marketed under different trade names depending on the region. JYNNEOS is the trade name used in the United States, while Imvamune is used in Canada and Imvanex is used in the European Union and European Economic Area.

---

Q: Are there different versions of Jynneos based on where you live?

The active vaccine product (MVA-BN) is the same regardless of location. However, health authorities in different regions have authorized different administration methods. For example, some have authorized a dose-sparing intradermal route in addition to the standard subcutaneous route, based on vaccine supply and public health need.

---

Q: Is it mandatory to receive Jynneos for certain jobs?

Health authorities describe JYNNEOS as being suitable for individuals at risk of occupational exposure, such as laboratory staff who handle orthopoxviruses. While this guidance is official, mandatory vaccination policies are determined by specific public health orders or individual employers.

---

Q: Can I donate blood after getting Jynneos?

Official blood donation guidance states that there is generally no mandatory deferral period required to donate blood after receiving the JYNNEOS vaccine. A person may donate blood as long as they feel well and are free of any symptoms.

Storage and Disposal Requirements for Jynneos

The storage and handling of Jynneos (Smallpox and Mpox Vaccine, Live, Non-replicating) are strictly defined by regulatory labeling to maintain product stability.

---

Storage Conditions

Condition	Required Temperature/Limit
Long-Term Storage	Frozen: -25 C to -15 C
Thawed Storage (Maximum 4 Weeks)	Refrigerated: +2 C to +8 C
Reconstituted Product (If applicable)	Refrigerated: +2 C to +8 C for leq 12 hours

Protection and Handling: The vaccine must be stored in its original carton to protect from light and must not be refrozen after it has been thawed. Vials should be allowed to reach room temperature before use. All product must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Jynneos and all associated waste materials must be disposed of in accordance with local requirements for pharmaceutical waste and must not be discarded via wastewater or household trash.